The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The promising feeder-free allogenic NK cell therapy: Clinical outcomes of GIC-102 monotherapy (GIC-102101) and synergistic potential with GI-101 (CD80-IgG4 Fc-IL2v) in advanced solid tumors and hematologic malignancies.
 
Soohyeon Lee
Stock and Other Ownership Interests - Celgene/Bristol-Myers Squibb; Pfizer
Consulting or Advisory Role - PharmAbcine
Research Funding - Jeil Pharmaceutical Co
Travel, Accommodations, Expenses - ST Cube
 
Junshik Hong
Honoraria - BMS Korea; Novartis; PharmaEssentia Korea
Consulting or Advisory Role - Bridgebio
Research Funding - Enzynomics
 
Hyungwoo Cho
No Relationships to Disclose
 
Woo Yul Lee
Employment - GI Cell; GI Innovation
Stock and Other Ownership Interests - GI Innovation
 
Do Soo Jang
Employment - GI Cell
Stock and Other Ownership Interests - GI Cell
 
YooJoon Lee
No Relationships to Disclose
 
Myoung Ho Jang
Employment - GI Innovation
Leadership - GI Innovation
Stock and Other Ownership Interests - GI biome; GI biome (I); GI Cell; GI Innovation
Consulting or Advisory Role - GI Cell
Patents, Royalties, Other Intellectual Property - GI biome; GI biome (I); GI Cell; GI Innovation
Other Relationship - Osaka university
 
Dok Hyun Yoon
Honoraria - Celgene; Janssen; Kirin Pharmaceuticals; Roche; Takeda
Consulting or Advisory Role - ABclonal; Amgen; Celgene; GI cell; Janssen; Novartis; Pharos iBio; Roche
Research Funding - Boryung; Celltrion (Inst); Janssen Oncology; Roche/Genentech; Samyang